Navigation Links
Onyx Pharmaceuticals Reports First Quarter 2011 Financial Results
Date:5/4/2011

SOUTH SAN FRANCISCO, Calif., May 4, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today reported its financial results for the first quarter 2011. Onyx reported a non-GAAP net loss of $14.2 million, or $0.23 per diluted share, for the first quarter 2011 compared to a non-GAAP net loss of $1.5 million, or $0.02 per diluted share, for the same period in 2010. Non-GAAP net loss excludes, among other items, adjustments to contingent consideration expense in connection with Onyx's acquisition of Proteolix Inc., or Proteolix; employee stock-based compensation expense; non-cash imputed interest expense related to the application of Accounting Standards Codification ("ASC") 470-20 and charges associated with the restructuring of Onyx's development, collaboration, option and license agreement with S*BIO Pte Ltd., or S*BIO.

"2011 is a pivotal year of execution and growth for Onyx as we prepare to deliver a number of significant near-term milestones," said N. Anthony Coles, M.D., president and chief executive officer of Onyx. "The NDA for carfilzomib in relapsed and refractory multiple myeloma is on track for filing; our Phase 3 confirmatory trials, ASPIRE and FOCUS, are enrolling patients; and ONX 0912, our next generation proteasome inhibitor, is expected to advance to Phase 2. Importantly, we are ramping up our preparation for the commercialization of carfilzomib, in anticipation of a potential U.S. launch next year."

On a GAAP basis, Onyx reported a net loss of $49.2 million, or $0.78 per diluted share, for the first quarter 2011 compared to a net loss of $12.0 million, or $0.19 per diluted share, for the same period in 2010. A description of the non-GAAP calculations and reconciliation to comparable GAAP measures is provided in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Net Loss."

Revenue from Collaboration Agreement
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014 GenSpera, Inc. ... the treatment of cancer, announces the recent publication of ... Steroids . The recent article co-authored ... the evolution and development of GenSpera,s prodrug technology platform that ... thapsigargin (from the plant Thapsia garganica ) directly ...
(Date:8/28/2014)... MONROVIA, Calif. , Aug. 28, 2014  STAAR Surgical ... and marketer of implantable lenses and delivery systems for the ... 2014 Health Care Conference at the New York Palace Hotel ... Barry Caldwell , President and CEO will ... financial results, and operational developments and be joined by ...
(Date:8/28/2014)... -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ... trials evaluating the use of collagenase clostridium histolyticum (CCH) for ... with a palpable cord will be presented at the upcoming ... Surgery of the Hand (ASSH) being held in ... (CCH) is a biologic approved in the U.S., EU, ...
Breaking Medicine Technology:GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3STAAR Surgical To Present At The Baird 2014 Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 2Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 3Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 4Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 5Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 6
(Date:8/28/2014)... To kick off the fall season ... One Spas retailers across the country are offering 0% ... The Hot Tub Tailgate Event is from August 29th-September ... more information and to apply early! , As the ... wide variety of outdoor hot tubs with exclusive features ...
(Date:8/28/2014)... 28, 2014) A fortuitous collaboration at Rice ... a recently discovered natural antibiotic. , The laboratory ... someday help bolster the fight against bacteria that ... around the world. , As part of ... structural biologist Yousif Shamoo and their colleagues created ...
(Date:8/28/2014)... researchers place glue directly on the nerve stumps, but ... and allows glue to easily invade the nerve ends. ... to insert the nerve ends into the conduit because ... Xiangdang Liang and co-workers from the General Hospital of ... technique and defined the best parameters for its use ...
(Date:8/28/2014)... be treated with nasal septum cells. Researchers at the ... cells taken from the nasal septum are able to ... can thus repair articular cartilage defects. The nasal cartilage ... environment is associated with the expression of so-called HOX ... has published the research results together with the report ...
(Date:8/28/2014)... OTTAWA, August 28, 2014 One in every 200 ... with the number of people living with the disease ... according to a study by researchers at the Institute ... Eastern Ontario (CHEO), and the Ottawa Hospital Research Institute. ... prevalence in the world. , The study, published this ...
Breaking Medicine News(10 mins):Health News:Synthesis produces new antibiotic 2Health News:Synthesis produces new antibiotic 3Health News:Synthesis produces new antibiotic 4Health News:From nose to knee: Engineered cartilage regenerates joints 2Health News:Ontario has one of the highest rates of IBD in the world 2
... caries can destroy most of a child,s teeth by ... Indians and Alaskan natives. Although the link between ... has been known for almost a century, progress in ... the disease has remained elusive. The ...
... The American College of Physicians (ACP) today told the ... including enacting a permanent end to scheduled Medicare sustainable ... for Congress to act was demonstrated by today,s release ... across-the-board cut in Medicare payments to doctors on January ...
... , THURSDAY, Nov. 3 (HealthDay News) -- Allergy ... costs and can now provide relief to allergy sufferers ... And while allergy shots are currently given under the ... investigated, delegates heard at this week,s annual scientific meeting ...
... the first time, researchers have combined gene therapy ... severe, crippling bleeding disorder hemophilia A in large ... new therapies for human patients. Researchers at ... Medicine, collaborating with other institutions, report in ...
... HealthDay Reporter , WEDNESDAY, Nov. 2 (HealthDay News) -- ... subset of hard-to-treat hemophilia patients also seems to be effective ... this study, published in the Nov. 3 edition of the ... one and didn,t last long, the results do raise the ...
... Men with locally advanced or high-risk prostate cancer who ... are less likely to die from their disease, shows ... Margaret Hospital (PMH) Cancer Program, University Health Network. ... Lancet (doi: 10.1016/S0140-6736(11)61095-7). Principal investigator Padraig Warde, ...
Cached Medicine News:Health News:NYUCD awarded $2.2 million NIH grant to decode genome of caries-causing bacteria 2Health News:NYUCD awarded $2.2 million NIH grant to decode genome of caries-causing bacteria 3Health News:Congress must 'go big' on physician payment reform 2Health News:Congress must 'go big' on physician payment reform 3Health News:Improved Allergy Shots Might Be on Horizon 2Health News:Gene therapy shows promise as hemophilia treatment in animal studies 2Health News:Using Drug for Prevention Might Help in Hard-to-Treat Hemophilia 2Health News:Using Drug for Prevention Might Help in Hard-to-Treat Hemophilia 3Health News:Radiation plus hormone therapy greatly improves survival 2
... Unique product designed for LASIK surgery ... to irrigate the corneal interface and/or stromal ... the flap and helps elevate the flap ... 7/8in (.40 x 22mm) Formed 9mm from ...
... designed for LASIK surgery and other types ... corneal interface and/or stromal bed. Flattened tip ... helps elevate the flap edge. Multiple ports ... x 22mm) Formed 9mm from end. Two ...
... designed for LASIK surgery and other ... irrigate the corneal interface and/or stromal ... under the flap and helps elevate ... multi-directional irrigation. 25G x 7/8in (.50 ...
... Cannula tip is specially ... insertion through wound and manipulation ... x 3.5mm, flexible tubing 25cm, ... 2mm. Unique annular rings ...
Medicine Products: